Efficacy of a novel compound in a humanized mouse model of psoriasis

Efficacy of a novel compound in a humanized mouse model of psoriasis - Pre-clinical efficacy of a novel compound in psoriasis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON36840

Enrollment

Registered

2012-08-21

Start date

2012-08-10

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

flaking disease psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use local corticosteroids or ointments to prevent dry skin (see Appendix 2).

Exclusion criteria

Exclusion criteria: These patients have not received light therapy or another form of systemic treatment (methotrexate, cyclosporin A, anti-TNF treatments). Gender or age of the adults are not exclusion criteria (see Appendix 2).

Design outcomes

Primary

Measure	Time frame
Effect on the psoriatic process is tested by histology and immuno-histochemical techniques in the transplanted biopsies. Main read-out is epidermal thickness.	—

Secondary

Measure	Time frame
Secretion of inflammatory mediators by cells from patients. Markers on cultured cells from psoriasis patients. Possibly also inflammatory cells in the skin tissue will be evaluated	—

Countries

Netherlands

Outcome results